BD (BDX) Receives Vizient Innovative Technology Contract for CentroVena One Insertion System

July 1, 2026 - 12:50

Becton, Dickinson and Company, known as BD and traded under the ticker BDX, has secured a notable designation for its CentroVena One Insertion System. On June 23, the company announced that Vizient, the largest provider-driven healthcare performance improvement firm in the United States, awarded the system an Innovative Technology contract.

This contract is a significant recognition for BD. It marks the CentroVena One Insertion System as a breakthrough technology that can improve patient care and operational efficiency. The system is designed to simplify and standardize the process of placing peripherally inserted central catheters, or PICC lines. By streamlining this common but complex procedure, the technology aims to reduce complications, save time for clinicians, and enhance patient outcomes.

The Vizient Innovative Technology program evaluates and endorses new medical products that offer clinical or operational advantages over existing options. For BD, this contract provides a pathway for the CentroVena One system to reach more hospitals and healthcare systems within the Vizient network. This endorsement can accelerate adoption and potentially lower costs for healthcare providers.

BD continues to focus on innovation in medication management and infusion therapy. The company is also considered a strong value stock by some analysts, given its consistent performance and broad portfolio of medical devices and diagnostic products. The Vizient contract adds to BD's momentum in the medical technology sector.